2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Supportive Care, Non-Biological Therapies, Pharmacology, Women’s Health, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3051 Clinical and genetic spectrum of congenital fibrinogen disorders in China: A retrospective analysis of 72 patients

Meiting Liang, Yuping Gong Sr, MD2
1 Department of Hematology, West China Hospital, Sichuan University, Chengdu, China, Chengdu, China
2 Department of Hematology, West China Hospital, Sichuan University, Chengdu, China

Background
Hereditary fibrinogen deficiency is a rare bleeding disorder caused by pathogenic variants in the FGA, FGB, or FGG genes, resulting in reduced fibrinogen levels and/or functional abnormalities. Large-scale, systematic studies characterizing the clinical and genetic features of this disorder in the Chinese population remain limited. This study aimed to investigate the clinical characteristics and genetic mutation spectrum of hereditary fibrinogen deficiency in a large cohort of Chinese patients.

Methods
A retrospective analysis was performed on 72 unrelated patients diagnosed with hereditary fibrinogen deficiency at West China Hospital, Sichuan University, between November 2018 and March 2026. Fibrinogen activity (FIB: C) was quantified using the Clauss method, and the ratio of Clauss FIB: C to PT-derived fibrinogen was calculated. Hypofibrinogenemia was defined as a Clauss/PT-derived fibrinogen ratio ≥ 0.47, and dysfibrinogenemia as a ratio < 0.47. All patients underwent targeted genetic testing, and clinical data, including bleeding and family history, were systematically collected.

Results
Of the 72 patients (22 males, 50 females; median age at diagnosis: 36.5 years), 64 had complete clinical documentation. The most common clinical presentations were incidental findings on routine laboratory testing (21/64, 32.8%), preoperative coagulation screening (16/64, 25.0%), bleeding manifestations (10/64, 15.6%), and pregnancy-related screening (10/64, 15.6%). Forty-six percent (26/64) of patients experienced at least one bleeding episode, with gingival bleeding and abnormal uterine bleeding the most prevalent. Patients with dysfibrinogenemia exhibited a significantly prolonged thrombin time compared with those with hypofibrinogenemia (30.9 ± 4.5 s vs. 25.0 ± 5.4 s, P < 0.001). Fibrinogen activity (FIB: C) showed a significant negative correlation with ISTH-BAT bleeding scores (r? = -0.264, P = 0.035). Genetic analysis identified 31 distinct pathogenic variants (12 novel), of which 22 (68.8%) were missense variants. The most common hotspot variants were FGA exon 2 c.104G>A (22 cases, 30.1%) and FGG exon 8 c.902G>A (15 cases, 20.5%), both detected exclusively in patients with dysfibrinogenemia. Nonsense variants (5.5%) were identified only in FGB and FGG and were associated with hypofibrinogenemia. Notably, FGB variants were exclusively found in patients with hypofibrinogenemia.

Conclusions
Genetic testing enables accurate subtyping and optimized family counseling/management of hereditary fibrinogen deficiency. Thrombin time may serve as a potential biomarker to distinguish qualitative from quantitative fibrinogen defects, particularly in resource-limited settings or large-scale screening programs.

Meiting Liang: No relevant conflicts of interest to declare.